Rapid Readouts: Phase 3 VIALE-A Study

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, colorectal cancer, multiple myeloma, and sarcoma.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.